Compare ADCT & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADCT | ZTR |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | Switzerland | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.8M | 357.2M |
| IPO Year | 2020 | N/A |
| Metric | ADCT | ZTR |
|---|---|---|
| Price | $3.41 | $6.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.60 | N/A |
| AVG Volume (30 Days) | ★ 582.0K | 219.4K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,209,000.00 | N/A |
| Revenue This Year | $12.48 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.35 | N/A |
| 52 Week Low | $1.05 | $4.50 |
| 52 Week High | $4.80 | $6.60 |
| Indicator | ADCT | ZTR |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 63.37 |
| Support Level | $3.51 | $6.23 |
| Resistance Level | $3.64 | $6.36 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 25.78 | 97.83 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.